Adolescent Medicine

Alcohol Abuse

Allergies and Infant Formula

Allergy, Immunology, and ENT

Animal Allergies

Autism

COVID-19

Cardiovascular Diseases

Cardiology

Atopic Dermatitis

Acne

Dermatology

Developmental/Behavioral Disorders

Diabetes

Drug Pipeline News

Emergency Medicine

Diabetes Type 2

Endocrinology

Gastroenterology

Gynecology

Antibiotic Resistance

Vaccination and Immunization

Bacterial Conjunctivitis

Vaccines

Infectious disease

Influenza

Anxiety

Depression

Mental Health

Concussion

Epilepsy

Headache

Neurology

Food Allergies

Obesity

Childhood Obesity

Nutrition

Neonatal/Perinatology

Obstetrics-Gynecology & Women's Health

Oncology

Pain

Pharmacology

Practice Improvement

ADHD

Antisocial Personality Disorder

Psychiatry

Asthma

Cystic Fibrosis

Pediatric Asthma

Pneumonia

Respiratory

Rheumatoid Arthritis

Sexually Transmitted Diseases

Sexual Health

Telemedicine

News 

All News

PNP Corner

AAP News

Media

Around the Practice

Cure Connections

Expert Interviews

Insights

Medical World News

Peer Exchange

Peers & Perspectives

Podcasts

Webinars

Puzzler

Publications

Contemporary Pediatrics Journal

Supplements And Featured Publications

CME/CE

Resources

Handouts

Job Board

Conferences

Conference Coverage

Conference Listing

Partnerships

Subscribe

Print Subscription

eNewsletter

Editorial

Editorial Advisory Board

Writer’s Guidelines

Reference Guidelines

Meet the Editors

Articles

Reduced sleep efficiency and increased sleep irregularity in adolescents and young adults with type 1 diabetes are associated with higher HbA1c levels, insulin resistance, and endothelial dysfunction, highlighting the significance of addressing sleep-related factors in diabetes care for improved overall health.

 Reduced sleep efficiency linked to higher HbA1c in type 1 diabetes teens

Joshua Fitch is an editor for Contemporary Pediatrics. 

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Contemporary Pediatrics week in review: FDA approved sickle cell treatments, pediatric pneumonia, and more

Sickle cell disease (SCD) patients aged 12 years and up can now be treated with exa-cel and lovo-cel, following simultaneous approval from the FDA on December 8, 2023. 

FDA approves pair of gene therapies to treat patients with sickle cell disease

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

RSV Roundtable: What clinicians are witnessing in terms of RSV incidence

About Us

Advertise

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Contemporary Pediatrics

Facebook

Twitter

LinkedIn

Instagram

Spotlight

2022 Best Tech

Changing Landscape in RSV Prevention

Food Insecurity and the Dangers of Infant Formula Dilution

Opt-Out Chlamydia Screening in Adolescent Care

Pediatric ADHD: Zeroing in on an Untenable Burden

The Role of the Healthcare Provider Community in Increasing Public Awareness of RSV in All Infants

Christopher Reist, MD

Articles